Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Weill Medical College of Cornell University
State University of New York at Buffalo
BeOne Medicines
Pathos AI, Inc.
GlaxoSmithKline
Janux Therapeutics
Weill Medical College of Cornell University
Merck Sharp & Dohme LLC
PROCEPT BioRobotics
AstraZeneca
Jiangsu HengRui Medicine Co., Ltd.
Genentech, Inc.
Vir Biotechnology, Inc.
Mayo Clinic
Eli Lilly and Company
Pfizer
Merck Sharp & Dohme LLC
City of Hope Medical Center
National Cancer Institute (NCI)
University of California, San Francisco
Eli Lilly and Company
University of Nebraska
Masaryk Memorial Cancer Institute
FindCure Biosciences (ZhongShan) Co., Ltd.
National Institutes of Health Clinical Center (CC)
University of California, San Francisco
Memorial Sloan Kettering Cancer Center
Canadian Cancer Trials Group
Novartis
Amgen
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Axonics, Inc.
Charles Drew University of Medicine and Science
Institute of Cancer Research, United Kingdom
Memorial Sloan Kettering Cancer Center
University of Nebraska
Thomas Jefferson University
NCBJ Polatom: Narodowe Centrum Badań Jądrowych Polatom
ABX advanced biochemical compounds GmbH
Canadian Cancer Trials Group
Canadian Cancer Trials Group
Astellas Pharma Inc
Wake Forest University Health Sciences
National Cancer Institute (NCI)
University of California, San Francisco
The New York Proton Center
Blue Earth Therapeutics Ltd
University of Alberta